Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10765628 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
US10632066 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
US10780047 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
US10925882 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
US11529308 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
US10940157 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
US10918649 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 2022-08-10
Market Authorisation Date: 10 August, 2018
Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of...
Dosage: RING;VAGINAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9301920 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10052386 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
US10639375 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
US8987237 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8993548 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11110099 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11103516 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10206932 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8846649 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8846648 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US9114146 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US9114145 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10675288 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11033626 | THERAPEUTICSMD INC | Progesterone formulations having a desirable pk profile |
Nov, 2032
(9 years from now) | |
US9006222 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10806740 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11103513 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8933059 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11166963 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8633178 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8993549 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 October, 2018
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10537581 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11246875 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11241445 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10835487 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US9289382 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10806697 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11351182 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11304959 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11497709 | THERAPEUTICSMD INC | NA |
Nov, 2032
(9 years from now) | |
US10568891 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
US10888516 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
US11116717 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
US11065197 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
US11123283 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
US10471072 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
US10668082 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
US9180091 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(10 years from now) | |
US10398708 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
US10258630 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
US11266661 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(10 years from now) |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic